DDInter899 DDInter1711
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved
Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs, hence boosting their therapeutic efficacy. Stiripentol may also exhibit direct anticonvulsant properties, although the exact mechanism of action is fully understood. Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit.
Stiripentol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Stiripentol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Stiripentol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fedratinib
Stiripentol {u} may lead to a major life threatening interaction when taken with {v} Venetoclax
Stiripentol {u} may lead to a major life threatening interaction when taken with {v} Naloxegol
Stiripentol may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Stiripentol may lead to a major life threatening interaction when taken with Venetoclax
Stiripentol may lead to a major life threatening interaction when taken with Naloxegol